Skip to main content
ConductScienceScienceDex

Charlotte Anne Casebourne Stock

FY2026 NIH rank #40,904
Unclaimed recordClaim profile
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 80082885Search this ID in NIH RePORTER
ORCID iD
No ORCID iD on recordA researcher can add one by claiming this profile.
ScienceDex PI coverage
FY2026 onlyCareer claims are limited to the years shown.

NIH Funding · FY2026

Linked Award Amount
$306.4K
Full award amounts, FY2026
Award Records
1
Records listing this PI
Award-Linked Rank
#40,904
By linked amount among FY2026 PIs
Earliest Year Loaded
2026
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Charlotte Anne Casebourne Stock. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2025 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award data coverage

ScienceDex currently has one fiscal year of PI ranking data for this record. This does not establish the first NIH award or current employer.

Single fiscal year on record (FY2026): $306.4K in linked award amounts across 1 award record · Award-linked rank #40904.

FY2026 award records by amount

NIH award records listing Charlotte Anne Casebourne Stock as a PI. Multi-PI records show the full award amount for context.

  • 1R41CA314730-01R41
    Novel combination immunotherapy with oncolytic adenovirus and immune checkpoint inhibitors for pancreatic ductal adenocarcinoma.
    Uinta Bio, Inc.
    $306.4K
    award amount

Award organization

Organizations that administered FY2026 awards listing Charlotte Anne Casebourne Stock as a PI.

FY2026 award administered by Uinta Bio, Inc. (UT).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2026
    First NIH Award
    Uinta Bio, Inc.

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Charlotte Anne Casebourne Stock.

Masato Yamamoto
Uinta Bio, Inc.
1
shared award

Explore further

Find collaborators for Charlotte Anne Casebourne Stock

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →